Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of “Hold” from Analysts

Sage Therapeutics, Inc. (NASDAQ:SAGE) has received an average recommendation of “Hold” from the seventeen research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and three have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $37.67.

A number of analysts have weighed in on SAGE shares. Truist Financial cut their price target on Sage Therapeutics from $22.00 to $18.00 and set a “hold” rating on the stock in a research note on Friday, April 26th. HC Wainwright dropped their price objective on shares of Sage Therapeutics from $28.00 to $25.00 and set a “neutral” rating on the stock in a research note on Friday, April 26th. Needham & Company LLC reissued a “hold” rating on shares of Sage Therapeutics in a research note on Thursday, April 25th. StockNews.com upgraded shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 27th. Finally, TD Cowen decreased their target price on Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, April 18th.

Institutional Investors Weigh In On Sage Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its stake in Sage Therapeutics by 95.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 748 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Sage Therapeutics by 17.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,289 shares of the biopharmaceutical company’s stock valued at $191,000 after buying an additional 1,375 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Sage Therapeutics in the 3rd quarter valued at approximately $219,000. Quest Partners LLC bought a new stake in shares of Sage Therapeutics in the 4th quarter valued at approximately $261,000. Finally, Handelsbanken Fonder AB grew its stake in shares of Sage Therapeutics by 29.8% in the 4th quarter. Handelsbanken Fonder AB now owns 12,644 shares of the biopharmaceutical company’s stock valued at $274,000 after buying an additional 2,900 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors.

Sage Therapeutics Trading Down 4.9 %

Shares of NASDAQ SAGE opened at $13.25 on Tuesday. The stock has a market cap of $797.39 million, a P/E ratio of -1.58 and a beta of 0.91. Sage Therapeutics has a 12-month low of $10.92 and a 12-month high of $59.99. The business’s fifty day simple moving average is $17.50 and its 200-day simple moving average is $20.41.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.17). The company had revenue of $7.90 million during the quarter, compared to analyst estimates of $5.26 million. Sage Therapeutics had a negative net margin of 552.52% and a negative return on equity of 56.81%. The firm’s revenue was up 139.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($2.46) earnings per share. On average, equities analysts forecast that Sage Therapeutics will post -6.53 EPS for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.